mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1421-9875|29|3|310-315

ISSN： 0257-2753

Source： Digestive Diseases, Vol.29, Iss.3, 2011-08, pp. : 310-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition

By  

Liver Cancer, Vol. 1, Iss. 3-4, 2012-11 ,pp. : 247-256

Karger

Access to resources Recommend Favorite

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells

By Bussiere C.   Lakey J.   Shapiro A.   Korbutt G.  

Diabetologia, Vol. 49, Iss. 10, 2006-10 ,pp. : 2341-2349

Springer Publishing Company

Access to resources Recommend Favorite

Systemic Treatment of Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 19, Iss. 4, 2002-03 ,pp. : 311-323

Karger

Access to resources Recommend Favorite

Treatment of Hepatocellular Carcinoma

By  

Digestion, Vol. 59, Iss. 5, 1998-08 ,pp. : 556-562

Karger

Access to resources Recommend Favorite

Treatment of Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 32, Iss. 5, 2014-07 ,pp. : 554-563

Karger

Access to resources Recommend Favorite